All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

2020-05-25T23:00:00.000Z

Pretransplant FLT3/ITD status as a prognostic marker for outcome in FLT3-mutated AML

May 25, 2020
Share:

Bookmark this article

Internal tandem duplication (ITD) of the juxtamembrane domain of the FMS-like tyrosine kinase-3 (FLT3/ITD) gene is a common mutation detected in 30% of patients with acute myeloid leukemia (AML) and is associated with poor survival outcomes and high relapse rates. However, a recent study has shown that these negative effects are only seen if the ratio of mutated to normal alleles is > 0.5, which adds to the controversy of the role of allogenic-stem cell transplantation (allo-SCT) in FLT3-mutated patients in their first complete remission (CR1).1

In a retrospective study, Grzegorz Helbig and colleagues from the Medical University of Silesia, Katowice, Poland, aimed to evaluate the potential factors that may have an impact on the outcome of FLT3-mutated patients after allo-SCT.1

Study design and patient characteristics

  • The study identified 43 adult patients with FLT3-mutated AML who were allografted between 2009–2019 from a database of medical records from the Medical University of Silesia
  • After AML diagnosis, patients were treated according to the Polish Adult Leukemia Group protocol
  • Induction therapy included daunorubicin, cytarabine, and cladribine
  • Consolidative chemotherapy consisted of two cycles of mitoxantrone with cytarabine, or cytarabine alone for patients that achieved complete remission (CR)
  • For patients with resistant disease after two inductions, three different salvage regimens were given according to the treating physician: CLAM (cladribine, cytarabine, and mitoxantrone), MEC (mitoxantrone, etoposide, and cytarabine), and FLAG-IDA (fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor [G-CSF])
  • FLT3/ITD mutational analysis was performed using multiplex fluorescence-based PCR at diagnosis, before conditioning commencement, and at Day 30 after allo-SCT
  • Patient characteristics are shown in Table 1 

Table 1. Patient characteristics1

FLT3/ITD, FMS-like tyrosine kinase-3/internal tandem duplication; MDS, myelodysplastic syndrome

Variable

Total patients

(N = 43)

 

Gender, female/male %

65.1/34.9

Median age, years (range)

45 (19–67)

Karyotype, %

 

Diploid

60

+ 8

9

− 5q

2

+ 11

2

inv9

2

− 7q

2

t(1;7)

2

+ 3,+ 13

2

no metaphases

19

Prior MDS, %

7

Hematologic response at transplant, %

 

First or second complete remission

79

Marrow aplasia

21

FLT3/ITD mutation at transplant, %

 

Negative

63

Positive

27

Median time from diagnosis to transplant, months (range)

16.7 (5.1–76.0)

 

  • 60% of patients had a normal diploid karyotype and the most common cytogenetic abnormality was trisomy 8 (9% of patients)
  • No induction death occurred and 70% of patients achieved CR1, a further 9% achieved complete remission after reintroduction (CR2), and 21% of patients were transplanted in marrow aplasia
  • Before transplant, 63% of patients had FLT3 measurable (minimal) residual disease (MRD) negativity
  • The median time from diagnosis to transplant was 16.7 months

Results

  • Acute graft-versus-host disease (GvHD) occurred in 58% of patients and chronic GvHD developed in 14% of patients
  • Postallograft CR rate was 88%, with 65% of patients achieving FLT3/ITD negativity at Day 30 after allo-SCT
  • Patients who were FLT3 MRD negative at transplant had a lower relapse incidence compared with those who remained FLT3 MRD positive (41% vs 59%; p = 0.01)
  • Patients who eradicated FLT3/ITD mutation at Day 30 posttransplantation had a significantly lower relapse incidence than those who had detectable FLT3/ITD (23% vs 76%; p < 0.001).
  • A strong positive correlation was shown between the posttransplant FLT3/ITD status and survival (r = 0.65; p < 0.001).
  • At transplant, 28 patients had MRD data measured by flow cytometry (MRD-FC), which showed a strong positive correlation between FLT3 MRD positivity and MRD-FC positivity (r = 0.53; p = 0.03).
  • The median overall survival (OS) and leukemia free survival (LFS) from allo-SCT were 28 months and 27 months, respectively
  • The 2-year OS and LFS were 54% and 53%, respectively
  • FLT3 MRD negativity at transplant prolonged LFS in multivariate analysis (HR, 5.3; 95% CI, 1.97–14.2; p < 0.001), whereas FLT3 MRD negativity and unrelated donor predicted a favorable OS (Table 2) 

Table 2. Univariate and multivariate analysis of risk factors for OS and LFS1

CI, confidence interval; FLT3/ITD, FMS-like tyrosine kinase-3/internal tandem duplication; HR, hazard ratio; LFS, leukemia-free survival; OS, overall survival

Outcome

Risk factor

Univariate analysis (log rank)

Multivariate analysis (Cox regression)

Survival at 2 years (%)

p value

HR (95% CI)

p value

OS

Type of donor

 

 

 

 

 

Related

19

0.010

0.35 (0.12–1.0)

0.050

 

Unrelated

68

 

 

 

 

FLT3/ITD status at transplant

 

 

 

 

 

Negative

74

0.001

2.67 (0.94–7.56)

0.060

 

Positive

21

 

 

 

LFS

Type of donor

 

 

 

 

 

Related

67

0.020

 

 

Unrelated

28

 

 

 

 

FLT3/ITD status at transplant

 

 

 

 

 

Negative

74

0.001

5.3 (1.97–14.2)

< 0.001

 

Positive

25

 

 

 

Conclusion

The strong positive correlation between FLT3 MRD positivity and MRD-FC positivity suggests that pretransplant detection of the FLT3/ITD mutation by PCR may serve as a reliable MRD marker and predict posttransplant outcome, particularly LFS, better than hematological disease status.

The authors note that although the study was limited by the small sample size, the results are in-line with other published studies. However, they suggest that further studies with larger numbers of patients are needed to draw final conclusions.

  1. Helbig G, Koclęga A, Wieczorkiewicz-Kabut A, et al. Pre-transplant FLT3/ITD status predicts outcome in FLT3-mutated acute myeloid leukemia following allogeneic stem cell transplantation. Ann Hematol. 2020. DOI: 1007/s00277-020-04026-1

Your opinion matters

HCPs, what is your preferred format for educational content on the AML Hub?
14 votes - 2 days left ...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox